Prothena Corp Public Ltd Co (PRTA) · Oct 29, 2026 · Agreement terminated

Prothena PRX019 termination wipes out $617.5M milestone upside

$617.5M milestones lost — Up to $617.5M in development, regulatory, and sales milestones plus royalties

Prothena’s PRX019 termination ends a partnered neurodegeneration program after Phase 1, eliminating up to $617.5M in future milestones and royalties.

Prothena is a late-stage neurodegeneration biotech whose partnered pipeline includes Roche’s Phase 3 prasinezumab, Novo Nordisk’s Phase 3 coramitug, and Bristol Myers Squibb’s Phase 2 moponetug; PRX019 was the earlier-stage, undisclosed-target addition to that portfolio.

BMS has stopped PRX019 before it became a meaningful pipeline asset. Bristol Myers Squibb decided not to advance the program, and the license agreement will terminate on January 28, 2027. 〔0〕 〔1〕

The economic hit is the loss of the program’s long-term upside, not a new near-term cash charge disclosed here. Prothena received the $80 million upfront payment in 2024, but it will no longer receive PRX019’s potential development, regulatory, or sales milestones of up to $617.5 million, or the associated royalties. 〔2〕

The decision is more negative because it came despite a clean Phase 1 profile, while the reason for stopping remains unclear. The trial met Prothena’s stated safety, immunogenicity, pharmacokinetic, and pharmacodynamic objectives, but those results were not enough for BMS to commit to further development. The filing does not identify whether the issue was efficacy confidence, target validation, commercial prioritization, or another strategic consideration. 〔3〕

The broader BMS relationship is damaged but not broken. BMS continues developing moponetug, Prothena’s tau-targeting Alzheimer’s antibody, in the Phase 2 TargetTau-1 trial; that is now the key remaining BMS-linked clinical asset to watch. Prothena says BMS has paid $135 million for moponetug and that up to $562.5 million in additional milestones remain available. 〔4〕

Bottom line: This removes a fully licensed clinical program and a substantial pool of contingent milestone and royalty value from Prothena’s pipeline. The remaining BMS relationship still matters, but the company now has less partnered breadth and more dependence on moponetug and its other collaborations.

What to watch next

TargetTau-1 Phase 2 completion, first half 2027

Original filing on SEC EDGAR

More Prothena Corp Public Ltd Co news

Prothena PRX019 termination wipes out $617.5M milestone upside | PRTA Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.